MedActuel - Syndrome coronarien aigu: l'angine instable et les NSTEMI (1ere et 2e parties)

Dans la majorité des cas, le syndrome coronarien aigu (SCA) survient lorsqu’une plaque d’athérome, située dans une artère coronaire, se fissure ou s’érode. Cette urgence thérapeutique se manifeste chez plus de 70 000 Canadiens chaque année et représente la deuxième cause de décès au pays.La mortalité liée au SCA a toutefois considérablement diminué ces 30 dernières années, notamment par la pratique d’interventions sophistiquées et l’emploi de thérapies médicamenteuses efficaces.Cet article propose de réviser les principes de traitement du SCA en se focalisant sur les agents pharmacologiques utilisés et sur les nouveautés de traitement.PDF des deux parties ci-contre.Références1. Lloyd-Jones D, Adams RJ, Brown TM, et coll. Executive Summary: Heart Disease and Stroke Statistics-2010 Update. Circulation 2010; 121(7): 948-54.2. Fitchett DH, Theroux P, Brophy JM, et coll. Assessment and management of acute coronary syndromes (ACS): A Canadian perspective on current guideline-recommended treatment - Part 1: Non-ST-segment elevation ACS. Can J Cardiol. 2011; 27: S387-S401.3. Agence de la santé publique du Canada. Suivi des maladies du cœur et des accidents vasculaires cérébraux au Canada 2009.4. Kumar A, Cannon CP. Acute coronary syndromes: Diagnosis and management, Part 1. Mayo Clin Proc. 2009; 84(10): 917-38.5. Institut canadien d’information sur la santé. Comprendre le syndrome coronarien aigu, 1re partie. Programme autodidacte 2008.6. O’Connor RE, Brady W, Brooks SC, et coll. Part 10: Acute coronary syndromes: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2010; 122: S787-S817.7. Trost JC, Lange RA. Treatment of acute coronary syndrome: Part 1: Non-ST-segment acute coronary syndrome. Crit Care Med. 2011; 39(10): 2346-53.8. Sabatine M, Antman EM. The thrombolysis in myocardial infarction risk score in unstable angina/non-ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2003; 41(4 Suppl S): 89S-95S.9. Antman EM, Cohen M, Bernink P, et coll. The TIMI risk score for unstable angina/non–ST elevation MI. JAMA 2000; 284(7): 835-42.10. Eagle KA, Lim MJ, Dabbous OH, et coll. A validated prediction model for all forms of acute coronary syndrome. JAMA. 2004; 291(22): 2727-33.11. Kirk J, Kontos M, Diercks D. Upstream treatment of acute coronary syndrome in the ED. Am J Emerg Med. 2011; 29(4): 446-56.12. Mehta SR, Granger CB, Boden WE, et coll. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med. 2009; 360(21): 2165-75.13. ISIS-4 (Fourth International Study of Infact Survival) Collaborative Group. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet. 1995; 345(8951): 669-85.14. Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994; 343(8906): 1115-22.15. Anderson JL, Adams CD, Antman EM, et coll. ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007. Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Circulation 2011; 123(18): e426-e579.16. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA. 1988; 260(15): 2259-63.17. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Blockade after myocardial infarction: Systematic review and meta regression analysis. BMJ. 1999; 318: 1730-7.18. The Danish Study Group on Verapamil in Myocardial Infarction. Verapamil in acute myocardial infarction. Eur Heart J. 1984; 5: 516-28.19. Jespersen CM. Verapamil in acute myocardial infarction. The rationales of the VAMI and DAVIT III trials. Cardiovasc Drugs ther. 2000; 14(1): 99-105.20. Pepine C, Faich G, Makuch R. Verapamil use in patients with cardiovascular disease: An overview of randomized trials. Clin Cardiol. 1998; 21(9): 633-41.21. Gibson R, Boden WE, Théroux P, et coll. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial. N Engl J Med. 1986; 315(7): 423-9.22. Gibson R, Hansen J, Messerli F, et coll. Long-term effects of diltiazem and verapamil on mortality and cardiac events in non-Q-wave acute myocardial infarction without pulmonary congestion: Post hoc subset analysis of the multicenter diltiazem postinfarction trial and the second danish verapamil infarction trial studies. Am J Cardiol. 2000; 86(3): 275-9.23. The Holland Interuniversity Nifedipine/Metoprolol Trial (HINT) Research Group. Early treatment of unstable angina in the coronary care unit: A randomised, double blind, placebo controlled comparison of recurrent ischæmiain patients treated with nifedipine or metoprolol or both. Br Heart J. 1986; 56(5): 400-13.24. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: Systematic overview of individual data from 100 000 patients in randomized trials. Circulation 1998; 97(22): 2202-12.25. Rodrigues E, Eisenberg MJ, Pilote L. Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction. Am J Med. 2003; 115(6): 473-9.26. Nguyen K, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: Subgroup analysis of the cooperative new scandinavian enalapril survival study II (CONSENSUS II). Am J Cardiol. 1997; 79(2): 115-9.27. Peterson J, Topol EJ, Sapp S, et coll. Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease. Am J Med. 2000; 109(5): 371-7.28. Leor J, Reicher-Reiss H, Goldbourt U, et coll. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: A cohort study of 11,575 patients with coronary artery disease. J Am Coll Cardiol. 1999; 33(7): 1920-5.29. Teo K, Yusuf S, Pfeffer M, et coll. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: A systematic review. Lancet. 2002; 360(9339): 1037-43.30. Latini R, Tognoni G, Maggioni AP, et coll. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: Systematic overview of individual data from 96,712 randomized patients. J Am Coll Cardiol. 2000; 35(7): 1801-7.31. Pfeffer MA, McMurray JJV, Velazquez EJ, et coll. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003; 349(20): 1893-906.32. Lewis HD, Davis JW, Archibald DG, et coll. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med. 1983; 309(7): 396-403.33. Théroux P, Ouimet H, McCans J, et coll. Aspirin, heparin, or both to treat acute unstable angina. N Eng J Med. 1988; 319(17): 1105-11.34. Cairns JA, Gent M, Singer J, et coll. Aspirin, sulfinpyrazone, or both in unstable angina. N Engl J Med. 1985; 313(22): 1369-75.35. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990; 336(8719): 827-30.36. The CURRENT-OASIS 7 investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010; 363(10): 930-42.37. Dib C, Hanna EB, Abu-Fadel MS. A new era for antiplatelet therapy in patients with acute coronary syndrome. Am J Med Sci. 2010; 340(5): 407-11.38. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345(7): 494-502.39. Mehta SR, Yusuf S, Peters RJG, et coll. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001; 358(9281): 527-33.40. Von Beckerath N, Taubert D, Pogatsa-Murray G, et coll. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel. Circulation 2005; 112(19): 2946-50.41. Montalescot G, Sideris G, Meuleman C, et coll. A randomized comparison of high clopidogrel loading doses in patients with non–ST-segment elevation acute coronary syndromes: The ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol. 2006; 48(5): 931-8.42. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: A review of the evidence. J Am Coll Cardiol. 2005; 45(8): 1157-64.43. Dorsch MP, Momary KM. Factors associated with clopidogrel nonresponsiveness. Future Cardiology 2010; 6(2): 195-210.44. Biancari F, Airaksinen KEJ, Lip GYH. Benefits and risks of using clopidogrel before coronary artery bypass surgery: Systematic review and meta-analysis of randomized trials and observational studies. Journal Thorac Cardiovasc Surg. 2012; 143(3): 665-75.45. Wiviott SD, Braunwald E, McCabe CH, et coll. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357(20): 2001-15. 46. Wallentin L, Becker RC, Budaj A, et coll. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361(11): 1045-57.47. The PURSUIT trial investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med. 1998; 339: 436-43.48. PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction (erratum publié dans N Engl J Med 1998; 339: 415). N Engl J Med. 1998; 338(21):1488-97.49. The CAPTURE investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997; 349(9063): 1429-35.50. The EPISTENT investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein- IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998; 352: 87-92.51. The EPILOG investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997; 336: 1689-96.52. The EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994; 330: 956-61.53. Boersma E, Harrington RA, Moliterno DJ, et coll. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: A meta-analysis of all major randomised clinical trials. Lancet 2002; 359(9302): 189-98.54. Antman EM, Cohen M, Radley D, et coll. Assessment of the treatment effect of enoxaparin for unstable angina/non–Q-wave myocardial infarction : TIMI 11B–ESSENCE Meta-Analysis. Circulation 1999; 100(15): 1602-8.55. Fifth organization to assess strategies in acute ischemic syndromes investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006; 354(14): 1464-76.56. Stone GW, McLaurin BT, Cox DA, et coll. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006; 355(21): 2203-16.57. Stary H, Chandler A, Glagov S, et coll. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb. 1994; 14: 840-56.58. Duriez P. Mécanismes de formation de la plaque d’athérome. Rev Med Interne 2004; 25(S1): S3-6.59. Lusis AJ, Mar R, Pajukanta P. Genetics of atherosclerosis. Annu Rev Genomics Hum Genet. 2004; 5: 189-

MedActuel - Syndrome coronarien aigu: l'angine instable et les NSTEMI (1ere et 2e parties)

Pour accéder au contenu, connectez-vous ou créez un compte gratuit.

Catégories connexes